Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.550 -0.020 (-1.27%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,590,594
Open	1.580
Bid (Size)	1.530 (10,000)
Ask (Size)	1.560 (2,500)
Prev. Close	1.570
Today's Range	1.520 - 1.590
52wk Range	1.105 - 3.180
Shares Outstanding	52,346,231
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

December 01, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK ↗

November 25, 2025

Via Stocktwits

Performance

YTD	-41.1%	-41.1%
1 Month	+9.9%	+9.9%
3 Month	+6.9%	+6.9%
6 Month	-31.4%	-31.4%
1 Year	-49.2%	-49.2%

More News

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

November 25, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

November 13, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

November 12, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

A Look at Autolus Therapeutics's Upcoming Earnings Report ↗

November 11, 2025

Via Benzinga

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

November 03, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

October 30, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

October 27, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

October 20, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 15, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

September 16, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

September 15, 2025

Via Investor Brand Network

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

September 15, 2025

Via FinancialNewsMedia

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

August 12, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

July 24, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

July 21, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 15, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

Via Benzinga

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

June 24, 2025

Via FinancialNewsMedia

What 4 Analyst Ratings Have To Say About Autolus Therapeutics ↗

June 12, 2025

Via Benzinga

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

June 12, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Frequently Asked Questions

Is Autolus Therapeutics plc - American Depositary Shares publicly traded?

Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.

What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?

Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?

The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market

What is the current price of Autolus Therapeutics plc - American Depositary Shares?

The current price of Autolus Therapeutics plc - American Depositary Shares is 1.550

When was Autolus Therapeutics plc - American Depositary Shares last traded?

The last trade of Autolus Therapeutics plc - American Depositary Shares was at 12/05/25 04:00 PM ET

What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?

The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 81.14M

How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?

Autolus Therapeutics plc - American Depositary Shares has 81M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.